|
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab
|
Aug 2020
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
|
Aug 2020
|
Lancet Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
|
Jul 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
|
Jul 2020
|
Blood
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
|
Jul 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
|
Jul 2020
|
Aging
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia
|
Jul 2020
|
Critical reviews in hematology/oncology
|
myelodysplastic syndromes (MDS)
|
|
Eat and be healthy: nutritional status in myelodysplastic syndromes
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes
|
Jul 2020
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
